Victory Square Technologies Inc.VST.CN
Key ratios
EPS growth
65.2%TTM
2025
99.9%
FCF / Sales
-16.1%TTM
2025
-9.0%2024
-3.0%2023
-26.4%
Net margin
7.3%TTM
2025
5.8%2024
7.4%2023
-117.4%
ROA
4.6%TTM
2025
-0.5%2024
-16.3%2023
-32.6%
ROE
21.4%TTM
2025
7.9%2024
44.2%2023
-268.4%
Revenue growth
320.8%TTM
2025
111.7%2024
38.7%2023
103.3%
Recent news
Victory Square Technologies Reports First-Half 2026 Revenue of $53.0 Million and Net Income of $6.5 Million
Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances
Track VST.CN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer